iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $0.02 · Revenue $222.45M · 7 analysts
Est. EPS $0.26 · Revenue $240.88M · 7 analysts
Est. EPS $-0.20 · Revenue $886.87M · 7 analysts
Est. EPS $-0.17 · Revenue $236.76M · 2 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $747.1M | +26.2% | +12.4% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-44.6M | +60.7% | +97.3% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +70.6% | +2.5% | +2.7% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -4.9% | +74.8% | +80.9% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -6.0% | +68.8% | +97.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $34.5M | +175.8% | +213.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +4.6% | +160.0% | +200.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 478.7% | -40.9% | -13.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.63x | -20.5% | -25.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $1.0B | +9.5% | +8.7% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.39 vs -1.50 | +7.4% | -0.01 vs 0.02 | -150.0% |
| Revenue Surprise | $747.1M vs $739.9M | +1.0% | $224.2M vs $222.4M | +0.8% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Wilson Daniel G. | officer: Chief Financial Officer | Common Stock | D | 773 | $121.83 |
| Aug 10, 2026 | Blackford Quentin S. | director, officer: President and CEO | Common Stock | D | 26,859 | $124.65 |
| Aug 10, 2026 | Murphy Patrick Michael | officer: CBO and CLO | Common Stock | D | 7,093 | $124.65 |
| Aug 10, 2026 | Patterson Chad | officer: CHIEF COMM & PRODUCT OFFICER | Common Stock | D | 7,093 | $124.65 |
| Aug 10, 2026 | Shrishrimal Sumi | officer: EVP, Chief Risk Officer | Common Stock | D | 5,372 | $124.65 |
Operator: Hello, everyone. Thank you for joining us, and welcome to the iRhythm Technologies, Inc. Q2 2026 Earnings Conference Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Lisa Pecora, Senior Vice President, Finance and Investor Relations. Lisa, please go ahead. Lisa Pecora: Thank you, operator, and thank you all for joining iRhythm's second quarter 2026 earnings call. With me today are Quentin Blackford, iRhythm's President and Chief Executive Officer, and Dan Wilson, our Chief Financial Officer. Before we begin, please note that management will make forward-looking statements within the meaning of Federal Securities Laws under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our intentions, beliefs, and expectations about future events, strategy, competition, products, operating plans, and performance. Forward-looking statements on this call are based on current estimates and assumptions, involve risks and uncertainties, and actual results may differ materially. These statements are made as of today, August 6th, 2026, and are time sensitive. We undertake no obligation to update or revise them except as required by law. Accordingly, you should not place undue reliance on these statements. For a discussion of risks and uncertainties, please refer to our most recent annual report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the SEC. Additionally, during the call, we will discuss certain financial measures that have not been prepared in accordance with GAAP. Unless otherwise noted, all references to financial measures on this call are presented on a non-GAAP basis. These non-GAAP measures should not be considered in isolation or as a substitute for or superior to GAAP results. Reconciliations to the most directly comparable GAAP measures can be found in our earnings release and the slides accompanying today's call. With that, I'll turn the call over to Quentin. Quentin Blackford: Good afternoon, everyone, and thank you for joining us. We had another very strong quarter, and I'm pleased to be here to discuss both our second quarter 2026 performance and the progress we are making against our long-term strategy. I will begin with a brief overview of the quarter, then discuss today's announced agreement to acquire VitalConnect, and finish with several key business updates. Dan will then talk about our financial performance and guidance in more detail. Second quarter revenue was $224.2 million, up 20.1% year-over-year. This marks our seventh consecutive quarter of growth above 20%, a meaningful accomplishment and a reflection of the durability of demand for Zio, the strength of our commercial execution, and …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Quentin S. Blackford | President, Chief Executive Officer & Director | USD 2,083,706 | Male | 1979 | Active |
Chad Patterson | Chief Commercial and Product Officer | USD 1,279,410 | Male | 1982 | Active |
Minang Turakhia | Chief Medical & Scientific Officer and Executive Vice President of Advanced Technologies | USD 1,033,085 | — | 1974 | Active |
Patrick Michael Murphy | Chief Business & Legal Officer | USD 987,343 | Male | 1979 | Active |
Daniel G. Wilson | Chief Financial Officer & Principal Financial Officer | USD 970,199 | Male | 1982 | Active |
Brian Lawrence | Executive Vice President & Chief Technology Officer | — | Male | 1970 | Active |
Lisa Pecora | Senior Vice President of Finance & Investor Relations | — | Female | — | Active |
Marc Rosenbaum | Senior Vice President of Finance & Chief Accounting Officer | — | Male | 1973 | Active |
Sean Clinton Freeman | Executive Vice President of Strategy & Corporate Development | — | Male | 1976 | Active |
Mervin Smith | Executive Vice President of Business Operations | — | Male | 1975 | Active |
SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
